Clearance profile of radioactive gold nanoparticle (198Au) conjugates-poliamidoamin generation 4-nimotuzumab ; potential radio-pharmaceutical theranostic agent
DOI:
https://doi.org/10.12928/pharmaciana.v7i2.6725Keywords:
gold nanoparticle, PAMAM, nimotuzumab, theranostic agent, clearanceAbstract
Theranostic agents are agents that combine diagnostic and therapeutic capabilities into a single agent. The presence of conjugated cancer which is therapeutic agents such as nimotuzumab monoclonal antibodies with radioactive gold nanoparticles stabilized with Polyamidoamine Generation 4 (PAMAM G4) dendrimer can actively interact with specific cancer cells. Radioactive gold (198Au) as a radiation transmitter β (961 keV) capable for killing cancer cells and (412 keV) γ rays that give a golden image in the body, thus acting as a theranostic agent. The purpose of this study was to obtain confident results of conjugate safety by observing the constituent clearance of 198AuNP-PAMAM G4-Nimotuzumab. The result of the conjugate clearance will be the reference for the metabolic state as a new, stable and complete radiofarmaka upon reaching the desired target. This study began with the synthesis of the conjugate of 198AuNp-PAMAM G4-nimotuzumab and then tested the clirens and analyzed the results of urine and mouse feces that had been injected with conjugate. Total clearance was obtained about 47.38% of the 198AuNP-PAMAM G4-Nimotuzumab conjugates that have been excreted through urine (18.26%) and stool (29.11%.). Urine and feces were analyzed with SDS-PAGE giving the spot above the 150 kDa band and showing the conjugate molecular weight. FTIR analysis of urine and feces by showing aldehyde functional groups (C = O), alcoholic groups (O-H), amine groups (C-N), and amine groups (N-H) indicating the presence of AuNP-PAMAM G4-Nimotuzumab conjugates in urine and mouse feces. The results of urine and fecal excretion of the conjugate are still conjugate-shaped supported by SDS PAGE analysis, UV-Vis spectrophotometer absorption analysis and functional group analysis with FTIR that has been conducted.
References
Ahmed, N., Fessi, H., & Elaissari, A., 2012, Theranostic applications of nanoparticles in cancer. Drug Discovery Today, 17(17-18), 928–934. http://doi.org/10.1016/j.drudis.2012.03.010
Barraza, L. F., Jiménez, Verónica A., & Alderete, Joel B., 2015, Effect of PEGylation on the Structure and Drug Loading Capacity of PAMAM-G4 Dendrimers: A Molecular Modeling Approach on the Complexation of 5-Fluorouracil with Native and PEGylated PAMAM-G4, Journal Macromolecular Chemistry and Physics, DOI: 10.1002/macp.201500179.
Gunawan, A. H., Pujianto, A., Maskur, Herlan S. & Rien R., 2014, Karakterisasi Senyawa Pengkontras Ct-Scan Terarah Aunp-PAMAM G4-Nimotuzumab Melalui Simulasi Menggunakan 198AuNP-PAMAM G4-Nimotuzumab, Jurnal Sains Materi Indonesia. Vol. 16, No. 1. ISSN: 1411-1098.
Gunawan, A. H., Pujianto, A., Mutalib, A., S. A. Rista, L. Indrariani, R. Rien, Y. M. Iyus, S. Herlan,
Herlan Setiawan, Anung Pujiyanto, Hotman Lubis, Mujinah, Dede Kurniasih, H., & Rien Ritawidya, A. M, (2012, Pembuatan Larutan H 198AuCl4 Dari Logam Emas, Prosiding Pertemuan Dan Presentasi Ilmiah - Penelitian Dasar Ilmu Pengetahuan Dan Teknologi Nuklir, (ISSN 0216 - 3128), 1–7.
Humani, T. S., Martoprawiro, M. A., & Mutalib, A., 2015, Temperature and Stretching Effects on Complementarity Determining Regions ( CDRs ) Conformation and Stability of Nimotuzumab F(ab) -Fragment, 41(1), 17–25. http://doi.org/10.17146/aij.2015.351
Nanjwade, B. K., Bechra, H. M., Derkar, G. K., Manvi, F. V, & Nanjwade, V. K, 2009, Dendrimers : Emerging polymers for drug-delivery systems, European Journal of Pharmaceutical Sciences, 38, http://doi.org/10.1016/j.ejps.2009.07.008
Ramli, M., Hidayat, B., Rustendi, C. T., Subur, M., Ardiyatno, C. N., Karyadi, K., … Masjhur, J. S, 2012, In Vitro and In Vivo Testing of 177Lu-DOTA-Nimotuzumab, a Potential Radioimmunotherapeutical Agent of Cancers. ITB Journal of Sciences, 44(4), 333–345. http://doi.org/10.5614/itbj.sci.2012.44.4.4
Sutriyo, Mutalib, A., Ristaniah, Anwar, E., Radji, M., Pujiyanto, A., … Adang, H. G, 2015, Synthesis of Gold Nanoparticles with Polyamidoamine (PAMAM) Generation 4 Dendrimer as Stabilizing Agent for CT Scan Contrast Agent. Macromolecular Symposia, 353(1), 96–101. http://doi.org/10.1002/masy.201550312
Sutriyo,Mutalib, A., Ristaniah, Anwar, E., Radji, M., Pujiyanto, A., … Adang, H. G2016, Profil Distribusi dan Klirens Pengkontras CT SCAN AuNP-PAMAM G4-Nimotuzumab disimulasikan menggunakan Senyawa 198AuNP-PAMAM G4-Nimotuzumab, J.Kim.Terap.Indonesia., 18(1). e-ISSN: 2527–7669
Sutriyo, 2015, Pembuatan dan Karakterisasi Konjugat Nanopartikel Emas Radioaktif(198Au)-Densrimer Poliamidoamin Generasi 4-Nimotuzumab Sebagai Agen Theranostic. Disertasi. Universitas Indonesia
Downloads
Published
Issue
Section
License
Authors who publish with Pharmaciana agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.